Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Palatin (PLTN) -- Ignore unavailable to you. Want to Upgrade?

To: Douglas who wrote (15)	12/12/1997 6:20:00 PM
From: Douglas	Read Replies (1) \| Respond to of 61

Palatin Tech Off 22%; Co. Cites End Of Lockup On Shrs By Sean Davis NEW YORK (Dow Jones)--Palatin Technologies Inc. (PLTN) fell 22% as 800,000 previously locked-up shares came on the market. Edward J. Quilty, the company's chairman, chief executive and president, said he didn't know who was selling the stock. But Palatin, a development-stage drug maker, sold the shares last spring in a private placement at $4.96 each, and Quilty said it was possible some of those investors were taking profits. Palatin opened Friday at 7 1/4, the high for the day. The issue recently traded at 5 5/8, up from the day low of 5 1/2, but off 22.4% from Thursday's close. Volume was 91,300, more than four times average daily volume of 20,500. The drop also follows a week in which other companies with male-impotence drugs in development saw their share prices decline. Palatin Executive Vice President Charles Putnam discounted the possibility that the company's shares were trading in sympathy with Vivus Inc. (VVUS) and Zonagen Inc. (ZNG), pointing out that Palatin acquired a license to Competitive Technologies Inc.'s (CTT) erectile-dysfunction drug only last month. "I don't think the market associates us with that sector," Putnam said. Palatin's lead product is LeuTech, a kit-packaged imaging agent targeted at appendicitis and other infections. Company-sponsored Phase I and II trials of LeuTech recently began. But Jay Abella, a biotechnology analyst at Westergaard Online, thinks treating male impotency will be important to Palatin. "Clearly, their strategy is to enhance shareholder value through the use of erectile-dysfunction products," Abella said. After Vivus said production delays would hurt fourth-quarter revenue, sellers took 31.4% off its market value. The male-impotency market, which the National Institutes of Health put at 10 million to 20 million people, has become a magnet for drug developers, with pharmaceuticals giants Pfizer Inc. (PFE) and Schering-Plough Corp. (SGP) set to enter. But Palatin's Putnam said the NIH estimate is higher than the company's internal estimate of 2 million. Based on the price of its license and the cost of the development that remains before the drug comes to market, Palatin's Putnam said the company would be happy with a total market of 2 million to 10 million men. - Sean Davis; 201-938-5400